---
title: "Sana Biotechnology plans IND filing, targets Phase 1/2 start this year for SC451 type 1 diabetes therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292486010.md"
description: "Sana Biotechnology plans to file an Investigational New Drug (IND) application for SC451, a hypoimmune stem cell-derived islet therapy for type 1 diabetes. The company targets the start of Phase 1/2 trials as early as this year. SC451 aims to be a potential one-time treatment achieving long-term normal blood glucose levels without the need for insulin therapy or immunosuppression."
datetime: "2026-07-13T12:07:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292486010.md)
  - [en](https://longbridge.com/en/news/292486010.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292486010.md)
---

# Sana Biotechnology plans IND filing, targets Phase 1/2 start this year for SC451 type 1 diabetes therapy

-   Sana set to file an IND application for SC451, a hypoimmune stem cell-derived islet therapy for type 1 diabetes. \* Phase 1⁄2 trial planned as early as this year, positioning SC451 as a potential one-time treatment. \* Program goal targets long-term normal blood glucose without insulin therapy or immunosuppression. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SANA.US](https://longbridge.com/en/quote/SANA.US.md)

## Related News & Research

- [SANA: Advancing hypoimmune cell therapies for T1D and in vivo CAR T cells, with key trials in 2026](https://longbridge.com/en/news/295462698.md)
- [HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings](https://longbridge.com/en/news/295787844.md)
- [FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets](https://longbridge.com/en/news/295537338.md)
- [Abeona Therapeutics Q2 net loss widens, misses analyst expectations](https://longbridge.com/en/news/295791975.md)
- [Sana Biotechnology (SANA) Projected to Release Earnings on Monday](https://longbridge.com/en/news/294704650.md)